S
Synendos Therapeutics
Developed first-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders
About Synendos Therapeutics
Synendos is a neuroscience startup that operates in the pharmaceutical industry, specifically focusing on neuropsychiatric disorders. The company's primary mission is to develop safe and effective therapies that can restore the natural functioning of the brain. The team, led by Dr. Andrea Chicca and Prof. Dr. Jürg Gertsch, both with extensive experience in the pharma industry and research on the endocannabinoid system (ECS), is working on a new drug target within the ECS.
Read full description
The ECS is a complex cell-signaling system that plays a role in regulating a range of functions and processes, including mood, appetite, sleep, and memory. Synendos' approach to treating neuropsychiatric disorders involves modulating this system to restore the brain's natural functioning.
Their lead drug candidate, SYT-510, is a Selective Endocannabinoid Re-uptake Inhibitor (SERI). In simple terms, SERIs are a new type of drug that can adjust the ECS to help it function better. This is a first-in-class drug, meaning it's the first of a new type of drugs that could potentially open a new way of treating neuropsychiatric disorders.
Synendos' business model revolves around the research, development, and eventual commercialization of these drugs. The company's primary clients would be healthcare providers and patients suffering from neuropsychiatric disorders. The company generates revenue through the sale of its pharmaceutical products once they have been approved for use.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Basel, Switzerland
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 83.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2021 | $3.7M | $92M | Ysios Capital | — |
| SERIES A✓Equity / VC | Nov 2020 | $18M | $73M | Schroder Adveq · BERNINA BioInvest · Kurma Partners · Sunstone Life Science Ventures | ↗ |
Growth signals
Latest recorded traffic for Synendos Therapeutics is 940 monthly website visits, up 42.4% over the last three months. Synendos Therapeutics's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Venture Kick
Series A6 investors entered at this stage
Kurma Partners
Sunstone Life Science Ventures
Schroder Adveq- BBBERNINA BioInvest
HTGF
Ysios Capital
Other known investors3 additional known investors
University of Bern
BaseLaunch
VentureLab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synendos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synendos Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.